Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Apellis Pharmaceuticals (APLS) Receivables - Other (2022 - 2025)

Apellis Pharmaceuticals filings provide 4 years of Receivables - Other readings, the most recent being $496000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Other fell 89.04% year-over-year to $496000.0, compared with a TTM value of $496000.0 through Dec 2025, down 89.04%, and an annual FY2025 reading of $496000.0, down 89.04% over the prior year.
  • Receivables - Other hit $496000.0 in Q4 2025 for Apellis Pharmaceuticals, down from $6.5 million in the prior quarter.
  • The five-year high for Receivables - Other was $6.5 million in Q3 2025, with the low at $496000.0 in Q4 2025.
  • Median Receivables - Other over the past 4 years was $4.4 million (2024), compared with a mean of $3.7 million.
  • The sharpest move saw Receivables - Other skyrocketed 181.72% in 2024, then plummeted 89.04% in 2025.
  • Year by year, Receivables - Other stood at $1.4 million in 2022, then soared by 111.79% to $3.1 million in 2023, then soared by 48.17% to $4.5 million in 2024, then crashed by 89.04% to $496000.0 in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $496000.0, $6.5 million, and $5.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.